Blood test could spot testicular cancer earlier

NCT ID NCT07376096

Not yet recruiting Diagnosis Sponsor: Medical University of Graz Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study explores whether a liquid biopsy—a blood test that looks for tumor DNA and micro RNA—can detect and monitor testicular germ cell tumors. Researchers will collect blood samples from 200 men with stage I or metastatic testicular cancer at several time points during treatment. The goal is to see if this test can help diagnose the disease and predict outcomes, especially for patients who do not have standard tumor markers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: liquid biopsy (blood test for circulating tumor DNA and micro RNA)
What this could lead to: If successful, this could provide a simple blood test to detect and monitor testicular cancer, especially for patients who lack standard tumor markers.
What could go wrong: This is an early-stage study with only 200 participants, and the test may not be accurate enough to replace current methods. It is not yet proven to work in routine care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for 100 METASTATIC PATIENTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

nongerminomatous germ cell tumor seminoma testicular germ cell tumor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

100 METASTATIC PATIENTS 100 STAGE I PATIENTS

More trials for these conditions

Other studies related to the condition(s) this trial covers.